The effect of nilotinib-mediated downregulation of MDM2 and XIAP on activation of p53 and caspases.

<p><b>A</b>, SUP-B15 (BCR-ABL+) and EU-1 (BCR-ABL–) were treated with 2 µM nilotinib for different times and different doses for 24 h, respectively. The expression of p53, p21 and PARP was detected by western blotting. <b>B</b>, cell-cycle analysis in SUP-B15 cells performed 4 h post-treatment with 2 µM nilotinib, as compared with untreated cells. <b>C</b> and <b>D</b>, activation of caspase-9 (C) and -3 (D) in nilotinib-treated SUP-B15 and EU-1 cells was detected by enzyme-linked immunosorbent assay (ELISA), *p>0.05.